Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cue Biopharma Announces $30 Million Private Placement
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma Announces 1-for-30 Reverse Stock Split
Cue Biopharma AGM: Shareholders Approve Reverse Stock Split, Elect Directors, Ratify Auditor
Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript
Cue Biopharma Announces CEO Transition
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
Cue Biopharma (NASDAQ:CUE) Shares Up 34.8% – What’s Next?
Cue Biopharma Announces Pricing of $10 Million Public Offering
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know
Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma to Host Business Update Call and Webcast
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma Announces Strategic Organizational Transition
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting